Journal article
Pseudodiastrophic dysplasia expands the known phenotypic spectrum of defects in proteoglycan biosynthesis
Alicia B Byrne, Shuji Mizumoto, Peer Arts, Patrick Yap, Jinghua Feng, Andreas W Schreiber, Milena Babic, Sarah L King-Smith, Christopher P Barnett, Lynette Moore, Kazuyuki Sugahara, Hatice Mutlu-Albayrak, Gen Nishimura, Jan E Liebelt, Shuhei Yamada, Ravi Savarirayan, Hamish S Scott
Journal of Medical Genetics | BMJ PUBLISHING GROUP | Published : 2020
Abstract
BACKGROUND: Pseudodiastrophic dysplasia (PDD) is a severe skeletal dysplasia associated with prenatal manifestation and early lethality. Clinically, PDD is classified as a 'dysplasia with multiple joint dislocations'; however, the molecular aetiology of the disorder is currently unknown. METHODS: Whole exome sequencing (WES) was performed on three patients from two unrelated families, clinically diagnosed with PDD, in order to identify the underlying genetic cause. The functional effects of the identified variants were characterised using primary cells and human cell-based overexpression assays. RESULTS: WES resulted in the identification of biallelic variants in the established skeletal dys..
View full abstractGrants
Awarded by NHMRC
Awarded by Australian Genomic Health Alliance NHMRC Targeted Call for Research into Preparing Australia for the Genomics Revolution in Healthcare
Awarded by Japan Society for the Promotion of Science
Funding Acknowledgements
This research was supported by the NHMRC (APP1123341) and the Australian Genomic Health Alliance NHMRC Targeted Call for Research into Preparing Australia for the Genomics Revolution in Healthcare (GNT1113531) to HSS and CPB; the Australian Cancer Research Foundation to HSS; Grant-in-A id for the Research Center for Pathogenesis of Intractable Diseases from the Research Institute of Meijo University to SM and SY; and Grant-in-A id for Scientific Research (C) 19K07054 from the Japan Society for the Promotion of Science to SM. Additional support was provided by Cancer Council SA's Beat Cancer Project on behalf of its donors and the State Government of South Australia through the Department of Health, and NHMRC Fellowship (APP1023059) to HSS; the Australian Government Research Training Program Scholarship and the Australian Genomics Health Alliance PhD Award and NHMRC (GNT1113531) to ABB; the Takeda Science Foundation to SM; and The Hospital Research Foundation Fellowship to PA.